Cadence Pharmaceuticals Inc (CADX) financial statements (2022 and earlier)

Company profile

Business Address 12481 HIGH BLUFF DRIVE
SAN DIEGO, CA 92130
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
12/31/2012
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments57,40154,30656,82364,240 
Cash and cash equivalents55,07551,98054,47760,495 
Short-term investments2,3262,3262,3463,745 
Restricted cash and investments548548640640 
Receivables9,3008,7118,9628,908 
Inventory, net of allowances, customer advances and progress billings8,6466,0947,3186,083
Inventory8,6466,0947,3186,083 
Prepaid expense1,9021,1831,659 
Prepaid expense and other current assets2,041 
Other current assets91124752 
Total current assets:77,88870,96676,15481,912 
Noncurrent Assets
Property, plant and equipment2,0601,8011,8941,905 
Intangible assets, net (including goodwill)10,74711,08211,41811,754
Intangible assets, net (excluding goodwill)10,74711,08211,41811,754 
Restricted cash and investments9292   
Other noncurrent assets168386 
Prepaid expense and other noncurrent assets90 
Total noncurrent assets:12,91513,05813,39813,749 
TOTAL ASSETS:90,80384,02489,55295,661 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities25,76619,85221,16718,340 
Accounts payable7,7244,4737,7695,808 
Accrued liabilities18,04215,37913,39812,532 
Debt10,7777,9375,1972,564 
Other undisclosed current liabilities   (12) 
Total current liabilities:36,54327,78926,36420,892 
Noncurrent Liabilities
Long-term debt and lease obligation18,53821,25123,86726,429 
Long-term debt, excluding current maturities18,53821,25123,86726,388 
Capital lease obligations   41 
Liabilities, other than long-term debt844604417233 
Other liabilities844604417233 
Other undisclosed noncurrent liabilities   (41) 
Total noncurrent liabilities:19,38221,85524,28426,621 
Total liabilities:55,92549,64450,64847,513 
Stockholders' equity
Stockholders' equity attributable to parent34,87834,38038,90448,148 
Common stock9999 
Additional paid in capital506,819502,203499,789497,158 
Accumulated deficit(471,950)(467,832)(460,894)(449,019) 
Total stockholders' equity:34,87834,38038,90448,148 
TOTAL LIABILITIES AND EQUITY:90,80384,02489,55295,661 

Income statement (P&L) ($ in thousands)

12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
12/31/2012
Q4
Revenues
(Revenue, Net)
35,31328,95724,67423,612 
Cost of revenue(11,548)(9,964)(8,294)(15,821) 
Cost of goods and services sold(11,548)(9,964)(8,294)(8,167) 
Gross profit:23,76518,99316,3807,791 
Operating expenses(26,621)(24,919)(27,169)(15,730) 
Other operating income (expense), net(161)107   
Other undisclosed operating income20    
Operating loss:(2,997)(5,819)(10,789)(7,939) 
Nonoperating income (expense)(1,121)(1,119)(1,086)6,576 
Other nonoperating income (expense)(1)(12)77,654 
Interest and debt expense(1,134)(1,122)(1,111)(1,100) 
Loss from continuing operations before equity method investments, income taxes:(5,252)(8,060)(12,986)(2,463) 
Other undisclosed income from continuing operations before income taxes4,467    
Net loss:(785)(8,060)(12,986)(2,463) 
Other undisclosed net income (loss) attributable to parent(3,333)1,1221,1111,100 
Net loss available to common stockholders, diluted:(4,118)(6,938)(11,875)(1,363) 

Comprehensive Income ($ in thousands)

12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
12/31/2012
Q4
Net loss:(785)(8,060)(12,986)(2,463) 
Comprehensive loss:(785)(8,060)(12,986)(2,463) 
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(3,333)1,1221,1111,100 
Comprehensive loss, net of tax, attributable to parent:(4,118)(6,938)(11,875)(1,363) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: